MBrace utilizes a unique antibody discovery methodology called SPARTA. SPARTA combines an in vitro screening step of a naïve human antibody library against tumor targets, with in vivo selections based on tumor-homing capabilities of a pre-enriched antibody pool. This unique approach overcomes several rate-limiting challenges for rapid translation into clinical applications.
Total raised: $85M
Investors 1
| Date | Name | Website |
| 31.12.2022 | Alta Partn... | altapartne... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.11.2023 | Series B | $85M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 14.11.2023 | MBrace Therapeutics Raises $85M in Series B Financing | MBrace Therapeutics, a San Diego, CA-based biopharmaceutical company, raised $85M in Series B fundin... | finsmes.co... |
| - | MBrace Therapeutics | “MBrace Therapeutics, Inc. | DEDICATED TO CANCER PATIENTS” | fastfounde... |